Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas.
about
Sesquiterpene lactones downregulate G2/M cell cycle regulator proteins and affect the invasive potential of human soft tissue sarcoma cellsDoxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcomaAdjuvant chemotherapy for localised resectable soft tissue sarcoma in adults.Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials.Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline.Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue SarcomasAdvanced chondrosarcomas: role of chemotherapy and survival.Pharmacotherapy of sarcoma.Role of chemotherapy in the management of soft tissue sarcomas.Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids.Pathology review in cancer research.Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines.Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.Olaratumab (Lartruvo): An Innovative Treatment for Soft Tissue Sarcoma.
P2860
Q21133015-8BF1BD40-684C-4849-A0A7-90B241CB4B02Q24247966-074627C0-8B9E-487C-B5D9-09107B145270Q34062253-0CC8BA38-B123-4D3E-95A9-713E50A9F079Q34633368-3C37A49D-50B5-4012-B3AE-8D7C438735AEQ36081538-B863DD8B-1227-495B-9FFF-E46771359D84Q36614418-13818731-73BD-47F3-8749-665147795B5CQ36619936-327B2F5E-82E8-4AE7-BBE9-8BE0C37F4C4CQ36674041-716A7273-1DB8-42E2-967F-497979EED2E7Q36674450-9509FF77-8554-437C-BF35-B2463ADE2B7CQ37265042-20460A1C-DF3A-4712-ACAC-259E29B6B9CEQ37532566-AEF3C55C-0C3E-419E-8133-6A1D93E3509AQ37687389-1B27B2EF-CAFB-4D6E-A981-7CD0A36553A6Q42138692-E8B63FD8-B7FB-4EA0-94E7-3A1928532286Q42389528-620BE921-3726-473B-ACDF-06D493997CF0Q44948239-B2B13CAC-175B-46BB-8EFE-A060065472A5Q47631238-3E9F5877-EC0A-46A9-88AB-2420BEEF9BABQ51285275-CAB29757-156C-4BD1-AF69-F6CD2A7916A8Q55123019-7E799816-7092-415F-9046-7A9BC9CD214C
P2860
Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Randomized comparison of doxor ...... tastatic soft-tissue sarcomas.
@en
Randomized comparison of doxor ...... tastatic soft-tissue sarcomas.
@nl
type
label
Randomized comparison of doxor ...... tastatic soft-tissue sarcomas.
@en
Randomized comparison of doxor ...... tastatic soft-tissue sarcomas.
@nl
prefLabel
Randomized comparison of doxor ...... tastatic soft-tissue sarcomas.
@en
Randomized comparison of doxor ...... tastatic soft-tissue sarcomas.
@nl
P2093
P1433
P1476
Randomized comparison of doxor ...... tastatic soft-tissue sarcomas.
@en
P2093
P304
P356
10.1002/1097-0142(19900901)66:5<862::AID-CNCR2820660509>3.0.CO;2-R
P407
P577
1990-09-01T00:00:00Z